Openbookopenbook
Equity
BioNTech SE(0A3M)
USD --+0.00%
Reward51Moderate
Risk38Moderate
📊50%Data
Thin -40% profit margin · Revenue down 24% YoY
0A3M
+0.0 · +0.00%
USD · LSE
BioNTech SE |
Earnings Deterioration
Market Cap:—
ℹ️
Reward Rating
51
Moderate
Bottom 50% (model universe)
50% data coverage
ℹ️
Risk Rating
38
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0A3M to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is BioNTech SE?

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany.

0A3M · Verdict

Moderate reward · moderate risk

0A3M stands out on balance sheet and cash flow, but watch the volatility signal.

Based on 75% data coverage

0A3M · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet89/100

    Top decile vs peers

  • Cash flow80/100

    Top decile vs peers

Watchouts 2

  • Volatility20/100

    Weak vs peers

  • Profitability44/100

    -6% return on equity

Model-based scoring. For information only — not financial advice.

What is BioNTech SE?

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. The company is listed on the LSE in UK.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Profitability metrics are mixed — margins may be under pressure.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (51)

The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market CapN/A
P/E Ratio0.032
Dividend YieldN/A
52 Week High125.7
52 Week Low79.51
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares OutstandingN/A
No. of Employees7,807
IndustryN/A
ExchangeLSE
Beta1.593
CurrencyUSD
Websitewww.biontech.de
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.